News

Under the deal, Medinet will license its new cell therapy technology to TC Biopharm for clinical development in the UK and Europe. The deal and subsequent commercialization is

UCB’s research arm UCB NewMedicines has used a new approach to identify small molecules modulators of a biological pathway, for which parenterally administered biologic therapies have proven highly

The product was determined to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Naloxone Hydrochloride Injection 0.4mg/mL, of Hospira. The injection is indicated for the

The patent, titled ‘Methods and Compositions for Oral Administration of Exenatide’, covers oral exenatide compositions made using Oramed’s proprietary technology, including its ORMD-0901 oral exenatide capsule. The company

DME occurs due to fluid leakage into the area of the retina. The sight-threatening condition occurs in type 1 and type 2 diabetes patients. ThromboGenics’ new biotherapeutics are

Under the terms of the license agreement, Access will receive an upfront licensing fee and double digit royalties on net sales of MuGard in the licensed territory. MuGard

The Phase III clinical program supporting Imbruvica’s early approval contained data that was collected and managed with BioClinica’s web-based solution and provided the Pharmacyclics team instant online access

Parexel provides a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. The company’s

The patent includes claims to the use of the company’s drug candidate, Trimesta (oral estriol), in conjunction with a gestagen for the treatment of multiple sclerosis (MS) and